Record Information |
---|
Version | 2.0 |
---|
Created at | 2012-09-06 15:16:51 UTC |
---|
Updated at | 2021-08-19 20:22:30 UTC |
---|
NP-MRD ID | NP0000033 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Cytarabine |
---|
Description | Cytarabine, or cytosine arabinoside, a pyrimidine nucleoside analog, is found in mushrooms. Cytarabine is isolated from the mushroom Xerocomus nigromaculatus of unknown palatability. Cytarabine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute myelogenous leukemia and meningeal leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle to stop normal cell development and division. Cytarabine is metabolized intracellularly into its active triphosphate form (cytosine arabinoside triphosphate). This metabolite then damages DNA by multiple mechanisms, including the inhibition of alpha-DNA polymerase, inhibition of DNA repair through an effect on beta-DNA polymerase, and incorporation into DNA. The latter mechanism is probably the most important. Cytotoxicity is highly specific for the S phase of the cell cycle. Cytarabine is a chemotherapy agent used mainly in the treatment of hematological malignancies such as acute myeloid leukemia (AML) and non-Hodgkin lymphoma. It is also known as ara C. Cytosine arabinoside is an antimetabolic agent with the chemical name of 1 -arabinofuranosylcytosine. Its mode of action is due to its rapid conversion into cytosine arabinoside triphosphate, which damages DNA when the cell cycle holds in the S phase (synthesis of DNA). Rapidly dividing cells, which require DNA replication for mitosis, are therefore most affected. Cytosine arabinoside also inhibits both DNA and RNA polymerases and nucleotide reductase enzymes needed for DNA synthesis |
---|
Structure | NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1 |
---|
Synonyms | Value | Source |
---|
1-beta-D-Arabinofuranosylcytosine | ChEBI | 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone | ChEBI | Ara-C | ChEBI | Arabinocytosine | ChEBI | Arabinoside C | ChEBI | Citarabina | ChEBI | Cytarabinum | ChEBI | Cytosine arabinoside | ChEBI | Cytosine-1-beta-D-arabinofuranoside | ChEBI | Cytosine-beta-D-arabinofuranoside | ChEBI | Depocyt | Kegg | 1-b-D-Arabinofuranosylcytosine | Generator | 1-Β-D-arabinofuranosylcytosine | Generator | 4-Amino-1-b-D-arabinofuranosyl-2(1H)-pyrimidinone | Generator | 4-Amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone | Generator | Cytosine-1-b-D-arabinofuranoside | Generator | Cytosine-1-β-D-arabinofuranoside | Generator | Cytosine-b-D-arabinofuranoside | Generator | Cytosine-β-D-arabinofuranoside | Generator | (beta-D-Arabinofuranosyl)cytosine | HMDB | 1-Arabinofuranosylcytosine | HMDB | 1-beta -D-Arabinofaranosylcytosine | HMDB | 1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone | HMDB | 1-beta -D-Arabinofuranosylcytosine | HMDB | 1-beta-D-Arabinofaranosylcytosine | HMDB | 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone | HMDB | 1-beta-D-Arabinofuranosyl-cytosine | HMDB | 1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside | HMDB | 1-beta-D-Arabinosyl-cytosine | HMDB | 1-beta-D-Arabinosylcytosine | HMDB | 1beta -Arabinofuranasylcytosine | HMDB | 1beta -D-Arabinofuranosylcytosine | HMDB | 1beta -D-Arabinosylcytosine | HMDB | 1beta-Arabinofuranasylcytosine | HMDB | 1beta-D-Arabinofuranosylcytosine | HMDB | 1beta-D-Arabinosylcytosine | HMDB | 2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl | HMDB | 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin | HMDB | 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine | HMDB | 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone | HMDB | 4-Amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one | HMDB | Alexan | HMDB | Arabinocytidine | HMDB | Arabinofuranosylcytosine | HMDB | Arabinosylcytosine | HMDB | Arabitin | HMDB | AraC | HMDB | Aracytidine | HMDB | Aracytin | HMDB | Aracytine | HMDB | Arafcyt | HMDB | beta -Arabinosylcytosine | HMDB | beta -Cytosine arabinoside | HMDB | beta -D-Arabinosylcytosine | HMDB | beta-Ara c | HMDB | beta-Arabinosylcytosine | HMDB | beta-Cytosine arabinoside | HMDB | beta-D-Arabinosylcytosine | HMDB | Cytarabin | HMDB | Cytarabina | HMDB | Cytarabine liposome injection | HMDB | Cytarabinoside | HMDB | Cytonal | HMDB | Cytosar | HMDB | Cytosar-u | HMDB | Cytosine 1-beta-D-arabinofuranoside | HMDB | Cytosine arabinofuranoside | HMDB | Cytosine arabinose | HMDB | Cytosine beta-D-arabinofuranoside | HMDB | Cytosine beta-D-arabinoside | HMDB | Cytosine, beta -D-arabinoside | HMDB | Cytosine, beta-D-arabinoside | HMDB | Cytosine-1-beta-D-arabinofuranoside hydrochloride | HMDB | Cytosine-beta -arabinoside | HMDB | Cytosine-beta -D-arabinofuranoside | HMDB | Cytosine-beta-arabinoside | HMDB | Cytosinearabinoside | HMDB | Depocyte | HMDB | Erpalfa | HMDB | Iretin | HMDB | Spongocytidine | HMDB | Tarabine | HMDB | Udicil | HMDB | Arabinoside, cytosine | HMDB | CytosarU | HMDB | Hydrochloride, cytarabine | HMDB | Cytarabine hydrochloride | HMDB | Cytosar u | HMDB | Ara C | HMDB | beta Ara C | HMDB | Cytarabine | MeSH |
|
---|
Chemical Formula | C9H13N3O5 |
---|
Average Mass | 243.2166 Da |
---|
Monoisotopic Mass | 243.08552 Da |
---|
IUPAC Name | 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one |
---|
Traditional Name | cytarabine |
---|
CAS Registry Number | 147-94-4 |
---|
SMILES | NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O |
---|
InChI Identifier | InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1 |
---|
InChI Key | UHDGCWIWMRVCDJ-CCXZUQQUSA-N |
---|
Experimental Spectra |
---|
|
| Spectrum Type | Description | Depositor Email | Depositor Organization | Depositor | Deposition Date | View |
---|
1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum | 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | Wishart Lab | Wishart Lab | David Wishart | 2021-06-20 | View Spectrum |
| Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrimidine nucleosides. Pyrimidine nucleosides are compounds comprising a pyrimidine base attached to a ribosyl or deoxyribosyl moiety. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Pyrimidine nucleosides |
---|
Sub Class | Not Available |
---|
Direct Parent | Pyrimidine nucleosides |
---|
Alternative Parents | |
---|
Substituents | - Pyrimidine nucleoside
- Glycosyl compound
- N-glycosyl compound
- Pentose monosaccharide
- Aminopyrimidine
- Pyrimidone
- Hydropyrimidine
- Monosaccharide
- Pyrimidine
- Imidolactam
- Tetrahydrofuran
- Heteroaromatic compound
- Secondary alcohol
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organic nitrogen compound
- Primary alcohol
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Amine
- Alcohol
- Organopnictogen compound
- Organic oxygen compound
- Primary amine
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Properties | |
---|
Predicted Properties | |
---|
General References | - Zaky DA, Betts RF, Douglas RG Jr, Bengali K, Neil GL: Varicella-zoster virus and subcutaneous cytarabine: correlation of in vitro sensitivities to blood levels. Antimicrob Agents Chemother. 1975 Mar;7(3):229-32. [PubMed:166610 ]
- Relling MV, Mulhern RK, Fairclough D, Baker D, Pui CH: Chlorpromazine with and without lorazepam as antiemetic therapy in children receiving uniform chemotherapy. J Pediatr. 1993 Nov;123(5):811-6. [PubMed:8229497 ]
- Mallick KS, Hajek AS, Parrish RK 2nd: Fluorouracil (5-FU) and cytarabine (ara-C) inhibition of corneal epithelial cell and conjunctival fibroblast proliferation. Arch Ophthalmol. 1985 Sep;103(9):1398-402. [PubMed:4038134 ]
- Bursztyn J, Boccara JF, Paillassou B, Bavoux F: [Corneal toxicity of cytarabine. Apropos of a case]. Ophtalmologie. 1989 Jun-Aug;3(3):229-30. [PubMed:2641118 ]
- Ohta T, Hori H, Ogawa M, Miyahara M, Kawasaki H, Taniguchi N, Komada Y: Impact of cytidine deaminase activity on intrinsic resistance to cytarabine in carcinoma cells. Oncol Rep. 2004 Nov;12(5):1115-20. [PubMed:15492802 ]
- (). Yannai, Shmuel. (2004) Dictionary of food compounds with CD-ROM: Additives, flavors, and ingredients. Boca Raton: Chapman & Hall/CRC.. .
|
---|